Literature DB >> 33407505

Circ_ZFR contributes to the paclitaxel resistance and progression of non-small cell lung cancer by upregulating KPNA4 through sponging miR-195-5p.

Junmin Li1, Rongmei Fan1, Hui Xiao2.   

Abstract

BACKGROUND: A growing body of evidence has demonstrated the vital roles of circular RNAs (circRNAs) in cancer progression and drug resistance. We intended to explore the roles and mechanisms of circ_ZFR in the paclitaxel (PTX) resistance and progression of non-small cell lung cancer (NSCLC).
METHODS: Two NSCLC cell lines A549 and H460 were used in this study. Quantitative real-time polymerase chain reaction (qRT-PCR) assay was conducted to measure the levels of circ_ZFR, ZFR, miR-195-5p and karyopherin subunit alpha 4 (KPNA4) mRNA. RNase R assay was used to analyze the characteristic of circ_ZFR. MTT assay was carried out to assess PTX resistance and cell proliferation. Flow cytometry analysis was utilized to analyze cell cycle and apoptosis. Transwell assay was used to examine cell migration and invasion. Western blot assay was conducted to measure the protein levels of Ki67, Twist1, E-cadherin and KPNA4. Dual-luciferase reporter assay was adopted to verify the combination between miR-195-5p and circ_ZFR or KPNA4. Murine xenograft model assay was used to investigate the effect of circ_ZFR on PTX resistance of NSCLC in vivo.
RESULTS: Circ_ZFR level was enhanced in PTX-resistant NSCLC tissues and cells. Knockdown of circ_ZFR suppressed PTX resistance, cell cycle process, proliferation, migration and invasion and induced apoptosis in PTX-resistant NSCLC cells. For mechanism analysis, circ_ZFR knockdown markedly downregulated the expression of KPNA4 by sponging miR-195-5p, thereby promoting PTX sensitivity and suppressing cell progression in PTX-resistant NSCLC cells. In addition, circ_ZFR silencing enhanced PTX sensitivity of NSCLC in vivo.
CONCLUSION: Circ_ZFR knockdown played a positive role in overcoming PTX resistance of NSCLC via regulating miR-195-5p/KPNA4 axis, which might provide a possible circRNA-targeted therapy for NSCLC.

Entities:  

Keywords:  Circ_zfr; KPNA4; NSCLC; PTX; miR-195-5p

Year:  2021        PMID: 33407505     DOI: 10.1186/s12935-020-01702-0

Source DB:  PubMed          Journal:  Cancer Cell Int        ISSN: 1475-2867            Impact factor:   5.722


  30 in total

Review 1.  New advances in immunotherapy for non-small cell lung cancer.

Authors:  Haifeng Qin; Fang Wang; Hui Liu; Zhen Zeng; Shasha Wang; Xin Pan; Hongjun Gao
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

Review 2.  The biogenesis, biology and characterization of circular RNAs.

Authors:  Lasse S Kristensen; Maria S Andersen; Lotte V W Stagsted; Karoline K Ebbesen; Thomas B Hansen; Jørgen Kjems
Journal:  Nat Rev Genet       Date:  2019-08-08       Impact factor: 53.242

Review 3.  Neoadjuvant and adjuvant therapy for Stage III non-small cell lung cancer.

Authors:  Shun-Ichi Watanabe; Kazuo Nakagawa; Kenji Suzuki; Kazuya Takamochi; Hiroyuki Ito; Jiro Okami; Keiju Aokage; Hisashi Saji; Hiroshige Yoshioka; Yoshitaka Zenke; Tadashi Aoki; Yasuhiro Tsutani; Morihito Okada
Journal:  Jpn J Clin Oncol       Date:  2017-12-01       Impact factor: 3.019

4.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

5.  Circular RNAs are a large class of animal RNAs with regulatory potency.

Authors:  Sebastian Memczak; Marvin Jens; Antigoni Elefsinioti; Francesca Torti; Janna Krueger; Agnieszka Rybak; Luisa Maier; Sebastian D Mackowiak; Lea H Gregersen; Mathias Munschauer; Alexander Loewer; Ulrike Ziebold; Markus Landthaler; Christine Kocks; Ferdinand le Noble; Nikolaus Rajewsky
Journal:  Nature       Date:  2013-02-27       Impact factor: 49.962

Review 6.  Non-small-cell lung cancer.

Authors:  Cesare Gridelli; Antonio Rossi; David P Carbone; Juliana Guarize; Niki Karachaliou; Tony Mok; Francesco Petrella; Lorenzo Spaggiari; Rafael Rosell
Journal:  Nat Rev Dis Primers       Date:  2015-05-21       Impact factor: 52.329

7.  Hsa_circ_0035483 sponges hsa-miR-335 to promote the gemcitabine-resistance of human renal cancer cells by autophagy regulation.

Authors:  Lei Yan; Guanghui Liu; Huixia Cao; Hongtao Zhang; Fengmin Shao
Journal:  Biochem Biophys Res Commun       Date:  2019-09-03       Impact factor: 3.575

8.  Pregnane X receptors regulate CYP2C8 and P-glycoprotein to impact on the resistance of NSCLC cells to Taxol.

Authors:  Yan Chen; Wandan Huang; Feiyu Chen; Guoping Hu; Fenglei Li; Jianhua Li; Aiguo Xuan
Journal:  Cancer Med       Date:  2016-11-22       Impact factor: 4.452

9.  Hsa_circ_0002483 inhibited the progression and enhanced the Taxol sensitivity of non-small cell lung cancer by targeting miR-182-5p.

Authors:  Xiaoping Li; Bo Yang; Haixia Ren; Ting Xiao; Liang Zhang; Lei Li; Mingjiang Li; Xuhui Wang; Honggang Zhou; Weidong Zhang
Journal:  Cell Death Dis       Date:  2019-12-16       Impact factor: 8.469

10.  Glucose-induced microRNA-218 suppresses the proliferation and promotes the apoptosis of human retinal pigment epithelium cells by targeting RUNX2.

Authors:  Rui Yao; Xiaoxi Yao; Ru Liu; Jingli Peng; Tao Tian
Journal:  Biosci Rep       Date:  2019-12-20       Impact factor: 3.840

View more
  13 in total

Review 1.  Advances in the Study of CircRNAs in Tumor Drug Resistance.

Authors:  Song Wang; Long Qian; Tingting Cao; Li Xu; Yan Jin; Hao Hu; Qingsheng Fu; Qian Li; Ye Wang; Jiawei Wang; Yabin Xia; Xiaoxu Huang
Journal:  Front Oncol       Date:  2022-05-09       Impact factor: 5.738

Review 2.  The Role of Circular RNAs in the Drug Resistance of Cancers.

Authors:  Xin-Yuan Liu; Qi Zhang; Jing Guo; Peng Zhang; Hua Liu; Zi-Bin Tian; Cui-Ping Zhang; Xiao-Yu Li
Journal:  Front Oncol       Date:  2022-01-05       Impact factor: 6.244

3.  Circ_0061140 knockdown inhibits tumorigenesis and improves PTX sensitivity by regulating miR-136/CBX2 axis in ovarian cancer.

Authors:  Jun Zhu; Jun-E Luo; Yurong Chen; Qiong Wu
Journal:  J Ovarian Res       Date:  2021-10-14       Impact factor: 4.234

Review 4.  Biogenesis, functions, and clinical implications of circular RNAs in non-small cell lung cancer.

Authors:  Ying Liu; Xiang Ao; Wanpeng Yu; Yuan Zhang; Jianxun Wang
Journal:  Mol Ther Nucleic Acids       Date:  2021-11-19       Impact factor: 8.886

5.  circ_ZFR Is Linked to Paclitaxel Resistance in Cervical Cancer via miR-944 Sponging and IL-10 Upregulation.

Authors:  Xiaoqian Long; Meiyun Zheng; Youlin Yang; Yi Chen; Xiahui Zhang; Haiyan Zhang
Journal:  Anal Cell Pathol (Amst)       Date:  2022-01-27       Impact factor: 2.916

6.  Circular RNA midline-1 (circMID1) promotes proliferation, migration, invasion and glycolysis in prostate cancer.

Authors:  Yafei Ding; Mi Wang; Jinjian Yang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

Review 7.  An Update on the Roles of circRNA-ZFR in Human Malignant Tumors.

Authors:  Lang Liu; Haicun Wang; Shaobo Yu; Xin Gao; Guanglin Liu; Dongsheng Sun; Xingming Jiang
Journal:  Front Cell Dev Biol       Date:  2022-02-02

8.  Circ_ZFR affects FABP7 expression to regulate breast cancer progression by acting as a sponge for miR-223-3p.

Authors:  Xiuling Tian; Hong Yang; Qian Fang; Hongmei Quan; Hongyu Lu; Xin Wang
Journal:  Thorac Cancer       Date:  2022-03-30       Impact factor: 3.223

9.  Circular RNA hsa_circ_0011298 enhances Taxol resistance of non-small cell lung cancer by regulating miR-486-3p/CRABP2 axis.

Authors:  Yihong Wu; Jieyun Xie; Han Wang; Shufang Hou; Jiuhuan Feng
Journal:  J Clin Lab Anal       Date:  2022-04-08       Impact factor: 3.124

Review 10.  Role of circular RNAs in the diagnosis, regulation of drug resistance and prognosis of lung cancer.

Authors:  Chengpeng Sang; Dingyu Rao; Caixia Wu; Yao Xia; Maoyan Si; Zhixian Tang
Journal:  Oncol Lett       Date:  2022-07-07       Impact factor: 3.111

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.